Scleroderma Lung Study Ii: Comparison Of Therapy With Mycophenolate Mofetil Versus Oral Cyclophosphamide In Patients With Symptomatic Scleroderma Interstitial Lung Disease

被引：0
|
作者：
Tashkin, D. P. [1 ]
Roth, M. D. [1 ]
Furst, D. E. [1 ]
Clements, P. [1 ]
Khanna, D. [2 ]
Volkmann, E. [1 ]
Kalafa, S. [1 ]
Goldin, J. [3 ]
Kim, G. H. J. [3 ]
Arriola, E. [4 ]
Tseng, C. -H. [4 ]
Elashoff, R. E. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] David Gefen Sch IMed, Los Angeles, CA USA
[4] David Geffen Sch Med, Los Angeles, CA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6432
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MYCOPHENOLATE MOFETIL VERSUS ORAL CYCLOPHOSPHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE: SCLERODERMA LUNG STUDY II
    Khanna, D.
    Roth, M.
    Clements, P.
    Furst, D.
    Tseng, C. -H.
    Elashoff, R.
    Volkmann, E.
    Kafaja, S.
    Goldin, J.
    Tashkin, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 531 - 531
  • [2] Mycophenolate mofetil for interstitial lung disease in scleroderma
    Plastiras, S. C.
    Vlachoyiannopoulos, P. G.
    Tzelepis, G. E.
    RHEUMATOLOGY, 2006, 45 (12) : 1572 - 1572
  • [3] EFFICACY OF MYCOPHENOLATE MOFETIL (MMF) VERSUS ORAL CYCLOPHOSPHAMIDE (CYC) ON SKIN THICKNESS IN THE SCLERODERMA LUNG STUDY II
    Khanna, D.
    Tashkin, D.
    Furst, D. E.
    Tseng, C. -H.
    Wilhalme, H.
    Roth, M.
    Kafaja, S.
    Volkmann, E.
    Elashoff, R.
    Clements, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 525 - 525
  • [4] MYCOPHENOLATE MOFETIL VERSUS CYCLOPHOSPHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE IN A REAL LIFE SCENARIO
    Fretheim, H.
    Midtvedt, O.
    Volkmann, E.
    Garen, T.
    Lund, M. B.
    Aalokken, T.
    Molberg, O.
    Hoffmann-Vold, A. -M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 106 - 106
  • [5] Mycophenolate mofetil for scleroderma-related interstitial lung disease
    Zaheen, Ahmad
    Stanbrook, Matthew B.
    Anand, Anju
    LANCET RESPIRATORY MEDICINE, 2016, 4 (11): : E53 - E53
  • [6] THE STABILIZATION OF LUNG FUNCTION IN PATIENTS WITH SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE DURING MYCOPHENOLATE MOFETIL THERAPY
    Koneva, O.
    Ananjeva, L.
    Korzeneva, L.
    Alekperov, R.
    Desinova, O.
    Starovoytova, M.
    Nevskaja, T.
    Ovsjannikova, O.
    RHEUMATOLOGY, 2012, 51 : 84 - 84
  • [7] DOUBLE-BLIND COMPARISON OF MYCOPHENOLATE MOFETIL AND ORAL CYCLOPHOSPHAMIDE FOR TREATMENT OF SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE (SCLERODERMA LUNG STUDY [SLS] II): RATIONALE, DESIGN, METHODS, BASELINE CHARACTERISTICS AND PATIENT DISPOSITION
    Khanna, D.
    Roth, M.
    Furst, D.
    Clements, P.
    Goldin, J.
    Arriola, E.
    Kotlerman, J.
    Tseng, C. -H.
    Kim, G.
    Elashoff, R.
    Tashkin, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 507 - 507
  • [8] MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM THE AUSTRALIAN SCLERODERMA COHORT STUDY
    Owen, C.
    Ngian, G.
    Moore, O.
    Stevens, W.
    Proudman, S.
    Roddy, J.
    Zochling, J.
    Nash, P.
    Hill, C.
    Sturgess, A.
    Sahhar, J.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 36 - 36
  • [9] Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease
    Arunsurat, Itthiphat
    Mahakkanukrauh, Ajanee
    Foocharoen, Chingching
    Suwannaroj, Siraphop
    Nanagara, Ratanavadee
    CLINICAL RHEUMATOLOGY, 2021, 40 (01) : 205 - 211
  • [10] Outcome of pulse oral cyclophosphamide therapy in scleroderma interstitial lung disease
    Itthiphat Arunsurat
    Ajanee Mahakkanukrauh
    Chingching Foocharoen
    Siraphop Suwannaroj
    Ratanavadee Nanagara
    Clinical Rheumatology, 2021, 40 : 205 - 211
12345